ResultsIQ

ResultsIQ › Latest results › CORONA Remedies Limited

CORONA Remedies Limited Q2 FY27 earnings call summary

NSE: CORONA · BSE: 544644

Earnings call of 2 Nov 2026, summarised by AI from the filing.

CORONA Remedies Q2 FY27 revenue ₹441 cr (+22.2%) with EBITDA margin 21.7%, and guides FY27 revenue growth of 15% and PAT growth of 20%.

Key takeaways

  1. Wokadine Integration and business-model change slower than expected; base sales maintained in Q2.
  2. Margin drag 400+ medical representatives added in Q4 FY26 weigh on EBITDA margin, which management expects to improve in coming years.

Original filing on BSE

CORONA Remedies Limited Q2 FY27 results

As filed: Revenue ₹441 cr, EBITDA ₹96.0 cr, PAT ₹60.2 cr, EBITDA margin 21.8%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%. Not scored. No result for the same quarter last year. Share price after the results: −0.9% in 28 days (Nifty 500: +0.3%).
  • Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
  • Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +5.9% in 30 days (Nifty 500: −1.9%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.